Investigated for use/treatment in cardiovascular disorders and coronary artery disease.
- Mechanism
- Curator reviewed
M118 is a novel drug candidate that has been, through Momenta's proprietary technology, rationally engineered with attributes of monitorability, reversibility, flexible administration (intravenous and subcutaneous), and both potent and predictable anti-Xa (aXa) and anti-IIa (aIIa) activity to provide anticoagulant therapy to patients with ACS. M118 is designed to interact at multiple points in the coagulation cascade by selectively binding to anti-thrombin III and thrombin, two critical factors in the formation of clots.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders and coronary artery disease.Curator reviewed
- Code names
- M-118
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Adomiparin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account